Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Immune Response to Influenza Vaccine in Pediatric Liver Transplant Recipients
NCT00133510Phase 4Completed
- Sponsor
- National Institute of Allergy and Infectious Diseases
- Start
- Nov 2004
- Modality
- Vaccines & Immunotherapeutics
- Countries
- 1
01
Overview
Phase 4, open-label trial of Fluzone Trivalent in influenza (2 arms), sponsored by National Institute of Allergy and Infectious Diseases. Primary endpoints: Humoral immune response at 8 weeks and Cell-mediated immune response at 8 weeks. Started Nov 2004; status: completed.
02
Drugs
Fluzone Trivalent
03
Conditions
influenza
Beyond the preview
Go deeper on NCT00133510.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00133510.